Gadolinium-Based Nanoparticles and Radiation Therapy for Multiple Brain Melanoma Metastases: Proof of Concept before Phase I TrialReport as inadecuate




Gadolinium-Based Nanoparticles and Radiation Therapy for Multiple Brain Melanoma Metastases: Proof of Concept before Phase I Trial - Download this document for free, or read online. Document in PDF available to download.

* Corresponding author 1 ILM - Institut Lumière Matière Villeurbanne 2 Department of Radiation Oncology 3 Nano-H SAS 4 GIN - Grenoble Institut des Neurosciences 5 Department of Neurosurgery, Erasmus University Hospital 6 LRCM EA3738 - Ciblage thérapeutique en Oncologie 7 HCL - Hospices Civils de Lyon - Centre hospitalier Lyon Sud 8 UGA UFRM - Université Grenoble Alpes - UFR Médecine

Abstract : Nanoparticles containing high-Z elements are known to boost the efficacy of radiation therapy. Gadolinium Gd is particularly attractive because this element is also a positive contrast agent for MRI, which allows for the simultaneous use of imaging to guide the irradiation and to delineate the tumor. In this study, we used the Gd-based nanoparticles, AGuIX®. After intravenous injection into animals bearing B16F10 tumors, some nanoparticles remained inside the tumor cells for more than 24 hours, indicating that a single administration of nanoparticles might be sufficient for several irradiations. Combining AGuIX® with radiation therapy increases tumor cell death, and improves the life spans of animals bearing multiple brain melanoma metastases. These results provide pre-clinical proof-of-concept for a phase I clinical trial.

Keywords : AGuIX radiosensitizer radiation therapy brain metastases nanoparticles imaged-guided therapy personalized medicine





Author: Shady Kotb - Alexandre Detappe - François Lux - Florence Appaix - Emmanuel Barbier - Vu-Long Tran - Marie Plissonneau - Hélène

Source: https://hal.archives-ouvertes.fr/



DOWNLOAD PDF




Related documents